

Release of Restricted Securities

Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), advises in accordance with ASX Listing Rule 3.10A, that the following securities, which were subject to voluntary escrow as part of the initial public offering in 2022, will be released from escrow as follows:

- 54,500,297 fully paid ordinary shares will be released from escrow on 27 January 2024; and
- 8,250,000 options will be released from escrow on 5 February 2024.

The release of the ordinary shares does not change the issued capital of the Company.

- Ends -

This announcement has been authorised for release by the Chairman and Chief Executive Officer.

For further information, please contact:

Dr Luke Reid
Chief Executive Officer
E: Luke.Reid@microba.com

Investor / Media Relations
E: investor@microba.com
W: <https://ir.microba.com/>
[Join our Investor Mailing List](#)

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

For more information visit: www.microba.com

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automatic Group.